Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
doi: 10.47626/2237-6089-2020-0078 201
We need to identify who benefits the most and focus our efforts there. Hwang is currently working on a follow-up project to refine clinical guidelines for prescribing GLP-1 drugs more selectively
Research applications In-vitro modeling of synergistic GHRH/GHRP receptor cross-talk Pre-clinical study of pulsatile GH-secretagogue dynamics Comparative receptor-pathway research (cAMP vs calcium convergence) Reference standard for analytical characterization of blended preparations Key facts Combines a GHRH-receptor analog with a selective GHS-R1a agonist Nominal 5mg + 5mg per-component loading per vial Components act through mechanistically independent, convergent pathways Supplied as a co-lyophilized research powder for in-vitro use Product specifications Class: GHRH analog + GHRP/ghrelin-receptor agonist research blend Also known as: Mod-GRF + Ipamorelin blend Form: Lyophilized powder vial Purity: 99% (HPLC verified) Testing: Independent third-party HPLC + mass spectrometry Documentation: Certificate of analysis per batch Storage: Store lyophilized at -20C
Amino acids make up 75% of the human body
